Daniel O'Day is the CEO of Gilead Sciences, a top player in the pharmaceutical industry known for its focus on treatments for serious diseases like HIV and hepatitis. He took the reins at Gilead on March 1, 2019, after a...

Daniel O'Day is the CEO of Gilead Sciences, a top player in the pharmaceutical industry known for its focus on treatments for serious diseases like HIV and hepatitis. He took the reins at Gilead on March 1, 2019, after a long and successful career at Roche Pharmaceuticals, where he spent over 30 years. With a strong background in biology from Georgetown University and an MBA from Columbia Business School, Daniel combines science with business savvy. Under his leadership, Gilead has made significant strides in health care innovation. In 2023, his compensation was over $22 million, mostly coming from performance-based stock awards that reflect how well the company is doing. He holds substantial shares in Gilead, worth about $35 million, which shows he's invested in the company's future. Daniel is all about aligning executive pay with company performance, making sure that both he and the shareholders benefit as Gilead grows. He has also demonstrated a commitment to innovation and tackling tough health challenges, positioning Gilead as a leader in the pharmaceutical landscape.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Gilead Sciences CEOs

G

Daniel O'Day

CEO of Gilead Sciences

Education

B.S. degree in biology from Georgetown University, M.B.A. from Columbia Business School

Field of Expertise

Healthcare & Life Sciences - Pharmaceuticals

Sector of Economy

Healthcare

Born

November 30, 1964 - 60 years ago

CEO of Gilead Sciences for

6 years 1 month (Mar 2019 - Present)

Previous Experience

CEO of Roche Pharmaceuticals

Rivals

Competitors/colleagues of Daniel O'Day

P

Albert Bourla

CEO of Pfizer

2023 Compensation

Stock

$0.00

Salary

$1.79M

Bonus

$0.00

Other

$2.26M

Total Holdings

$18.38M

M

Robert M. Davis

CEO of Merck & Co.

2023 Compensation

Stock

$17.72M

Salary

$1.60M

Bonus

$0.00

Other

$386.15K

Total Holdings

$5.80M

M

Stéphane Bancel

CEO of Moderna

2023 Compensation

Stock

$0.00

Salary

$1.58M

Bonus

$1.91M

Other

$1.07M

Total Holdings

$491.74M

V

Reshma Kewalramani

CEO of Vertex Pharmaceuticals

2022 Compensation

Stock

$10.64M

Salary

$1.40M

Bonus

$3.78M

Other

$43.06K

Total Holdings

$54.25M

V

Marianne De Backer, MSc, Ph.D., MBA

CEO of Vir Biotechnology, Inc.

2023 Compensation

Stock

$5.80M

Salary

$675.00K

Bonus

$855.36K

Other

$437.18K

Total Holdings

$5.17M

L

John L. Higgins

CEO of Ligand Pharmaceuticals

2022 Compensation

Stock

$0.00

Salary

$730.46K

Bonus

$0.00

Other

$0.00

Total Holdings

$48.52M

Holdings

See how much did Daniel O'Day make over time.

Daniel O'Day has a strong stake in Gilead Sciences, with his common stock holdings valued at over $35 million. His investments reflect his belief in the company's future. Since taking over as CEO in 2019, he has accumulated a significant...

Daniel O'Day has a strong stake in Gilead Sciences, with his common stock holdings valued at over $35 million. His investments reflect his belief in the company's future. Since taking over as CEO in 2019, he has accumulated a significant number of restricted stock units as well, which keep him deeply involved in Gilead's long-term performance. This shows that he is not only a leader but also someone who has a lot to gain when the company does well. Over recent years, there have been interesting shifts in his wealth, as stock values fluctuate with the company's performance. His holdings peaked notably after Gilead's successful treatments gained significant market attention, indicating how much his own financial success is tied to the health and innovation of the company.

Loading...

Insider Trading

See recent insider trades of Daniel O'Day.

GILD

224,504 shares

GILD

Feb 4, 2025

Received

GILD

230,747 shares

GILD

Jan 31, 2024

Received

GILD

215,017 shares

GILD

Jan 24, 2023

Received

GILD

146,678 shares

GILD

Jan 26, 2022

Received

GILD

59,100 shares

GILD

Jan 26, 2021

Received

GILD

19,204 shares

GILD

Jan 29, 2020

Received

Compensation History

See how much did Daniel O'Day make over time.

In 2023, Daniel O'Day's total compensation reached about $22 million. This includes a base salary of around $1.7 million and nearly $16.5 million from vested stock awards based on company performance. Gilead emphasizes performance-based pay, which means O'Day's earnings are closely linked to how well the company performs. His compensation strategy shows a strong focus on meeting financial goals and corporate strategies. The compensation committee at Gilead takes a rigorous approach to ensure that his pay reflects the company’s success, aligning his interests with those of the shareholders. Daniel's pay has consistently included substantial performance stocks that reward him for achieving strategic objectives of the company, ensuring that he is driven to lead Gilead towards continued success.

Year

2023

Total Compensation

$19.46M

Salary

$1.74M

Board Justification

Gilead's compensation philosophy focuses on attracting and retaining top talent while aligning executive compensation with company performance and shareholder interests.

Bonus

$0.00

Board Justification

No bonus was awarded for 2023 as part of the annual incentive plan.

Other

$1.22M

Board Justification

Other compensation includes contributions to the deferred compensation plan and perquisites such as security and travel expenses.

Restricted Stock

$16.51M(200.34K RSU)

Board Justification

The stock awards that vested in 2023 were primarily performance shares and restricted stock units earned based on corporate performance metrics.

Performance Metrics

Performance metrics for 2023 included financial results and strategic goals, with a corporate performance factor of 124%.

Other Gilead Sciences CEOs

Here are other CEOs of Gilead Sciences

Gregg Alton

Ex-CEO of Gilead Sciences

January 2019 - March 2019